Quantum Biopharma (TSE:QNTM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quantum BioPharma’s safety review committee has recommended moving forward with dosing the second cohort in its Phase 1 clinical trial for Lucid-21-302, targeting multiple sclerosis. This decision comes after positive safety evaluations from the first cohort, marking a significant step in the company’s innovative drug development efforts.
For further insights into TSE:QNTM stock, check out TipRanks’ Stock Analysis page.